MX2020012295A - Composiciones de fusosoma y usos de estas. - Google Patents
Composiciones de fusosoma y usos de estas.Info
- Publication number
- MX2020012295A MX2020012295A MX2020012295A MX2020012295A MX2020012295A MX 2020012295 A MX2020012295 A MX 2020012295A MX 2020012295 A MX2020012295 A MX 2020012295A MX 2020012295 A MX2020012295 A MX 2020012295A MX 2020012295 A MX2020012295 A MX 2020012295A
- Authority
- MX
- Mexico
- Prior art keywords
- fusosome
- target cell
- regulatory element
- compositions
- specific regulatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671838P | 2018-05-15 | 2018-05-15 | |
| US201862695529P | 2018-07-09 | 2018-07-09 | |
| PCT/US2019/032488 WO2019222403A2 (en) | 2018-05-15 | 2019-05-15 | Fusosome compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012295A true MX2020012295A (es) | 2021-03-31 |
Family
ID=67303499
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012295A MX2020012295A (es) | 2018-05-15 | 2019-05-15 | Composiciones de fusosoma y usos de estas. |
| MX2025008552A MX2025008552A (es) | 2018-05-15 | 2020-11-13 | Composiciones de fusosoma y usos de estas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025008552A MX2025008552A (es) | 2018-05-15 | 2020-11-13 | Composiciones de fusosoma y usos de estas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210228627A1 (https=) |
| EP (1) | EP3793570A2 (https=) |
| JP (2) | JP7568513B2 (https=) |
| KR (2) | KR20260042239A (https=) |
| CN (1) | CN112367973A (https=) |
| AU (1) | AU2019269593A1 (https=) |
| BR (1) | BR112020023015A2 (https=) |
| CA (1) | CA3099497A1 (https=) |
| IL (1) | IL278665B2 (https=) |
| MX (2) | MX2020012295A (https=) |
| SG (1) | SG11202011015QA (https=) |
| WO (1) | WO2019222403A2 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| CA3062426A1 (en) | 2017-05-08 | 2018-11-15 | Flagship Pioneering Innovations V, Inc. | Compositions for facilitating membrane fusion and uses thereof |
| CN112955174A (zh) | 2018-07-09 | 2021-06-11 | 旗舰先锋创新V股份有限公司 | 融合剂脂质体组合物和其用途 |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| CN113631718A (zh) | 2018-11-14 | 2021-11-09 | 旗舰先锋创新V股份有限公司 | 用于特定隔室货物递送的组合物和方法 |
| AU2019378883A1 (en) * | 2018-11-14 | 2021-06-03 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for T cell delivery |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2020252455A1 (en) * | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| CA3152525A1 (en) | 2019-09-03 | 2021-03-11 | Sana Biotechnology, Inc. | Cd24-associated particles and related methods and uses thereof |
| CN114828885A (zh) * | 2019-12-10 | 2022-07-29 | 瑞普利金公司 | 制备病毒载体的方法 |
| CA3178308A1 (en) * | 2020-03-31 | 2021-10-07 | Sana Biotechnology, Inc. | Targeted lipid particles and compositions and uses thereof |
| CA3189601A1 (en) | 2020-07-24 | 2022-01-27 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| WO2022055894A1 (en) * | 2020-09-08 | 2022-03-17 | The Regents Of The University Of California | Sars-cov-2 spike glycoprotein for virus generation and pseudotyping |
| MX2023008081A (es) * | 2021-01-11 | 2023-09-12 | Sana Biotechnology Inc | Uso de vectores virales dirigidos a cd8. |
| EP4298228A4 (en) * | 2021-02-23 | 2025-09-24 | Mayo Found Medical Education & Res | Genetically engineered hemagglutinin and fusion polypeptides from canine distemper virus |
| KR20240028975A (ko) | 2021-04-08 | 2024-03-05 | 사나 바이오테크놀로지, 인크. | Cd8-특이적 항체 구조체들 및 이의 조성물 |
| JP2024521811A (ja) | 2021-05-28 | 2024-06-04 | サナ バイオテクノロジー，インコーポレイテッド | 短縮型ヒヒ内在性レトロウイルス（ＢａＥＶ）エンベロープ糖タンパク質を含む脂質粒子、ならびに関連する方法及び使用 |
| EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| CN114032239B (zh) * | 2021-10-28 | 2024-06-21 | 北京美康基免生物科技有限公司 | 一种组织特异启动子及其应用 |
| EP4426828A1 (en) | 2021-11-01 | 2024-09-11 | Tome Biosciences, Inc. | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
| EP4433579A4 (en) * | 2021-11-18 | 2026-03-18 | Broad Inst Inc | Retargeted retroviral vectors resistant to vaccine-induced neutralization and compositions or methods of use thereof |
| US20250059239A1 (en) | 2021-12-17 | 2025-02-20 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
| WO2023115041A1 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
| EP4463135A2 (en) * | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4472646A1 (en) | 2022-02-01 | 2024-12-11 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
| WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024220560A1 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Engineered protein g fusogens and related lipid particles and methods thereof |
| EP4698666A1 (en) | 2023-04-18 | 2026-02-25 | Sana Biotechnology, Inc. | Universal protein g fusogens and adapter systems thereof and related lipid particles and uses |
| EP4716750A1 (en) | 2023-05-23 | 2026-04-01 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025224182A2 (en) | 2024-04-23 | 2025-10-30 | Basecamp Research Ltd | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL78703A (en) | 1985-05-10 | 1993-02-21 | Benzon Alfred | Method of producing extracellular enzymes, the enzymes produced thereby and compositions containing them; a hybrid plasmid and a dna fragment comprising dna encoding the enzymes; a microorganism harbouring the plasmid; and a method for removing nucleic acids from biological materials |
| AU2589095A (en) | 1994-05-16 | 1995-12-05 | Washington University | Cell membrane fusion composition and method |
| AU6691496A (en) * | 1995-08-01 | 1997-02-26 | Advanced Therapies, Inc. | Enhanced artificial viral envelopes for cellular delivery of therapeutic substances |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| PT904392E (pt) | 1996-10-17 | 2001-06-29 | Oxford Biomedica Ltd | Vectores retrovirais |
| WO1999013905A1 (en) | 1997-09-18 | 1999-03-25 | The Trustees Of The University Of Pennsylvania | Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery |
| GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| ES2373406T3 (es) | 1997-12-22 | 2012-02-03 | Oxford Biomedica (Uk) Limited | Vectores basados en el virus de la anemia infecciosa equina (vaie). |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| DE69938931D1 (de) * | 1998-09-23 | 2008-07-31 | Inst Virologie Teilrechtsfaehi | Retrovirale partikel, geschützt gegen komplementvermittelte lyse |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| JP2004502426A (ja) * | 2000-07-05 | 2004-01-29 | トランジェーヌ、ソシエテ、アノニム | 平滑筋の発現を制御するキメラプロモーター |
| CA2325088A1 (en) * | 2000-12-01 | 2002-06-01 | Fusogenix Inc. | Novel membrane fusion proteins derived from poikilothermic reovirus |
| WO2002088346A2 (en) | 2001-05-01 | 2002-11-07 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
| US20040028687A1 (en) | 2002-01-15 | 2004-02-12 | Waelti Ernst Rudolf | Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues |
| AU2003258060B2 (en) | 2002-03-27 | 2007-07-12 | Baylor College Of Medicine | Potent oncolytic herpes simplex virus for cancer therapy |
| EP2339010B1 (en) | 2002-05-01 | 2017-04-12 | Miltenyi Biotec Technology, Inc. | Lentiviral vector particles resistant to complement inactivation |
| ATE360683T1 (de) | 2002-05-14 | 2007-05-15 | Merck & Co Inc | Verfahren zur reinigung von adenovirus |
| WO2004045582A1 (en) | 2002-11-21 | 2004-06-03 | Pevion Biotech Ltd. | High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them |
| WO2005059111A2 (en) | 2003-12-17 | 2005-06-30 | The Trustees Of Columbia University In The City Of New York | DELIVERY OF DNA OR RNA VIA GAP JUNCTIONS FROM HOST CELLS TO TARGET CELLS AND A CELL-BASED DELIVERY SYSTEM FOR ANTISENSE OR SiRNA |
| WO2006027202A1 (en) | 2004-09-06 | 2006-03-16 | Unite De Recherche En Biotherapie Et Oncologie (Rubio) | Generation of multiparent cell hybrids |
| AU2005306801B2 (en) | 2004-11-08 | 2012-05-17 | The Regents Of The University Of Colorado | Structure-based compound design involving riboswitches |
| CA2609142C (en) | 2005-05-27 | 2016-02-09 | Fondazione Centro San Raffaele Del Monte Tabor | Therapeutic gene vectors comprising mirna target sequences |
| WO2007099387A1 (en) | 2006-03-03 | 2007-09-07 | Mymetics Corporation | Virosome-like vesicles comprising gp41-derived antigens |
| WO2008071959A1 (en) * | 2006-12-12 | 2008-06-19 | Oxford Biomedica (Uk) Limited | Lentiviral vectors comprising micrornas |
| US9050269B2 (en) | 2009-03-10 | 2015-06-09 | The Trustees Of The University Of Pennsylvania | Protection of virus particles from phagocytosis by expression of CD47 |
| EP2498823B1 (en) | 2009-11-13 | 2018-08-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Direct protein delivery with engineered microvesicles |
| WO2012156839A2 (en) | 2011-05-19 | 2012-11-22 | Ospedale San Raffaele S.R.L. | New generation of splice-less lentiviral vectors for safer gene therapy applications |
| KR20150029756A (ko) * | 2011-06-10 | 2015-03-18 | 블루버드 바이오, 인코포레이티드. | 부신백질이영양증 및 부신척수신경병증을 위한 유전자 요법 벡터 |
| US20160289674A1 (en) | 2012-04-02 | 2016-10-06 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
| KR102396026B1 (ko) * | 2014-01-21 | 2022-05-09 | 안자리움 바이오사이언시스 아게 | 하이브리도좀, 이를 포함하는 조성물, 이의 제조 방법 및 이의 용도 |
| GB201412494D0 (en) * | 2014-07-14 | 2014-08-27 | Ospedale San Raffaele And Fond Telethon | Vector production |
| US20180163178A1 (en) * | 2015-05-29 | 2018-06-14 | Robert J. Schneider | Auf1 encoding compositions for muscle cell uptake, satellite cell populations, and satellite cell mediated muscle generation |
| US20170112773A1 (en) | 2015-10-23 | 2017-04-27 | Board Of Regents, The University Of Texas System | Plasma membrane vesicles comprising functional transmembrane proteins |
| WO2017151717A1 (en) * | 2016-03-01 | 2017-09-08 | French Brent A | Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells |
| EP3235908A1 (en) * | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| WO2017211945A1 (en) * | 2016-06-09 | 2017-12-14 | Alma Mater Studiorum Universita Di Bologna | Herpesvirus with modified glycoprotein h for propagation in a cell |
| CA3030003A1 (en) * | 2016-07-08 | 2018-01-11 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| WO2018022747A1 (en) * | 2016-07-26 | 2018-02-01 | Senti Biosciences, Inc. | Genetic erasers |
| MA45783A (fr) | 2016-07-29 | 2019-06-05 | Juno Therapeutics Inc | Procédés d'évaluation de la présence ou de l'absence d'un virus compétent pour la réplication |
| AU2019215063B2 (en) * | 2018-02-01 | 2025-10-16 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing Factor VIII |
-
2019
- 2019-05-15 SG SG11202011015QA patent/SG11202011015QA/en unknown
- 2019-05-15 IL IL278665A patent/IL278665B2/en unknown
- 2019-05-15 BR BR112020023015-4A patent/BR112020023015A2/pt unknown
- 2019-05-15 CA CA3099497A patent/CA3099497A1/en active Pending
- 2019-05-15 AU AU2019269593A patent/AU2019269593A1/en active Pending
- 2019-05-15 KR KR1020267005235A patent/KR20260042239A/ko active Pending
- 2019-05-15 US US17/055,077 patent/US20210228627A1/en active Pending
- 2019-05-15 JP JP2020564225A patent/JP7568513B2/ja active Active
- 2019-05-15 MX MX2020012295A patent/MX2020012295A/es unknown
- 2019-05-15 KR KR1020207036111A patent/KR102930875B1/ko active Active
- 2019-05-15 WO PCT/US2019/032488 patent/WO2019222403A2/en not_active Ceased
- 2019-05-15 EP EP19740433.8A patent/EP3793570A2/en active Pending
- 2019-05-15 CN CN201980045045.1A patent/CN112367973A/zh active Pending
-
2020
- 2020-11-13 MX MX2025008552A patent/MX2025008552A/es unknown
-
2024
- 2024-05-20 JP JP2024081800A patent/JP7815327B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL278665B2 (en) | 2024-10-01 |
| KR20260042239A (ko) | 2026-03-30 |
| KR20210021473A (ko) | 2021-02-26 |
| BR112020023015A2 (pt) | 2021-02-17 |
| JP7815327B2 (ja) | 2026-02-17 |
| JP2024098072A (ja) | 2024-07-19 |
| KR102930875B1 (ko) | 2026-02-26 |
| SG11202011015QA (en) | 2020-12-30 |
| WO2019222403A2 (en) | 2019-11-21 |
| CA3099497A1 (en) | 2019-11-21 |
| JP7568513B2 (ja) | 2024-10-16 |
| IL278665A (https=) | 2021-03-01 |
| EP3793570A2 (en) | 2021-03-24 |
| AU2019269593A1 (en) | 2020-11-26 |
| IL278665B1 (en) | 2024-06-01 |
| US20210228627A1 (en) | 2021-07-29 |
| WO2019222403A3 (en) | 2019-12-12 |
| CN112367973A (zh) | 2021-02-12 |
| JP2021523724A (ja) | 2021-09-09 |
| MX2025008552A (es) | 2025-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020012295A (es) | Composiciones de fusosoma y usos de estas. | |
| MX2021000308A (es) | Composiciones de fusosoma y usos de estas. | |
| AU2019378883A8 (en) | Fusosome compositions for T cell delivery | |
| WO2020102499A3 (en) | Fusosome compositions for cns delivery | |
| CO2019009258A2 (es) | Administración rápida y controlada de composiciones con efectos séquito restaurados | |
| MX2021000459A (es) | Metodo para producir celulas t gamma y delta. | |
| BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
| BR112018004620A2 (pt) | moduladores da expressão de kras | |
| BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| CO2017013065A2 (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) | |
| JOP20210050A1 (ar) | معدلات تعبير pnpla3 | |
| MX2018005745A (es) | Control de niveles redox celulares. | |
| CL2020002052A1 (es) | Composiciones de edb que se dirigen a il-12. | |
| BR112021022514A2 (pt) | Conjugados de anticorpo e fármaco | |
| BR112016006048A8 (pt) | composições antimicrobianas | |
| CR20190471A (es) | Moduladores de la expresión de pcsk9 | |
| UY37800A (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO | |
| CO2020008769A2 (es) | Moduladores de la expresión dnm2 | |
| MX2018014419A (es) | Composicion y metodos para la terapia de microbiota. | |
| MX2016012248A (es) | Composiciones para el tratamiento de autodigestion. | |
| BR112017001888A2 (pt) | formulações biológicas para instilação intravesical | |
| BR112018071695A2 (pt) | composições e métodos para a expressão gênica acentuada de pklr | |
| CL2021001246A1 (es) | Moduladores de expresión irf5. | |
| MX2023008764A (es) | Composiciones y metodos para prevenir y tratar afecciones. |